OR WAIT null SECS
14th edition attracted 59 commercial plans as respondents, representing 100 million lives
The 14th edition EMD Serono’s Specialty Digest continues its insights into the worries of pharmacy directors at managed care organizations and health plans. This year, the Digest took a particular look at multiple sclerosis (one of EMD Serono’s product areas) as well.
According to respondents, managing costs and evaluating value are the key drivers overall—no surprise there. Despite high interest, 25% of respondents noted that “determining value of specialty drugs” was their least successful goal to be achieved in the past year; conversely, “ensuring clinically appropriate use” was their most successful goal. There is a mixed message regarding the entrance of biosimilars: While the expectation of seeing prices 25% below those of the originator products has faded (only 3% of respondents expect this), respondents upped their expected cost savings from 6% in 2016 to 9% in 2017.
Among other results noted from the respondents:
"This year's Specialty Digest reveals noteworthy findings – particularly the increase of infusion site-of-care programs and rise in physician collaboration for cancer treatment development – that we believe will serve as an important benchmarking tool in this highly complex managed care environment," said Robert Truckenmiller, SVP, market access & customer solutions.
The survey was conducted during October-November, 2017, to “commercial health plan personnel who are responsible for specialty drug-related services.” The full report is available at http://specialtydigest.emdserono.com.